Glioblastoma multiforme (GBM) is the most dangerous and aggressive form of brain cancer. Chimeric antigen receptor (CAR)-modified T cells can mediate long-term durable remissions in recurrent or refractory CD19+ B cell malignancies, and are a promising therapy to treat GBM. Epidermal growth factor receptor variant III, EGFRvIII is one of the GBM tumor antigens expressed in about 30% of glioblastomas. EGFRviii is a mutated form of EGFR protein, a neo-antigen, and is not expressed in normal tissues.